Latest Content

In an interview with CURE, Dr. Lakshmi Nayak explains how an FDA label update expands Yescarta access for relapsed or refractory primary CNS lymphoma.

Cancer-related fatigue may persist despite improved sleep or treated depression, underscoring it as a distinct and complex symptom.

Dr. William Audeh discusses how genomic subtyping can close the 38% mortality gap for Black women by identifying aggressive basal-type cancers.

Rodney Haring discusses Indigenous navigation, partnerships and prevention strategies to reduce cancer disparities and improve equity in Native communities

The FDA cleared an IND for FG001, allowing a U.S. trial in high-grade glioma, with first patient enrollment expected in second quarter of 2026.

Genentech announces FDA acceptance of giredestrant plus Afinitor for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer treatment.

Thsi overview explains mesothelioma staging, diagnosis, side effects and treatment options from frontline through later lines to guide patient discussions.

Learn about Kaposi sarcoma causes, symptoms and the latest treatment options to help you navigate your diagnosis and talk with your oncologist.

Dr. Rodney Haring discusses strategies to reduce cancer mortality among Native Americans through patient navigation, clinical trials and tribal sovereignty.

Dr. Alex Francoeur of UC Irvine urges patients with ovarian cancer to ask questions, seek second opinions and build trusted relationships with oncologists.

A study led by Dr. J. William Harbour of UT Southwestern Medical Center marks a shift in how doctors predict the spread of uveal melanoma.

Gratitude didn’t erase my fear, but it gave me something solid to stand on. It became the coping strategy I needed.